ABT vs AZN: stock comparison and AI forecast
Abbott Laboratories (ABT) and Astrazeneca Plc (AZN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ABT Abbott Laboratories
- Price
- $109.40 +25.5% · 6M
- Market Cap
- $190.23B
- P/E Ratio
- 30.6x
- Size
- large-cap
- AI Forecast
AZN Astrazeneca Plc
- Market Cap
- $285.01B
- P/E Ratio
- 13.3x
- Size
- mega-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- AZN is 1.5 times larger than ABT by market capitalization ($285.01B against $190.23B).
- AZN trades at 13.3 times trailing earnings, ABT at 30.6 times.
- AZN turns 15.4% of its revenue into net income, against 13.9% for ABT.
- AZN carries 1.34 times debt per unit of equity, against 1.11 times for ABT.
- ABT yields 2.20% in dividends; AZN pays none.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ABT | AZN |
|---|---|---|
| Market Cap | $190.23B | $285.01B |
| P/E Ratio | 30.64x | 13.28x |
| P/B Ratio | 3.65x | – |
| Dividend Yield | 2.20% | – |
| EPS | $3.57 | $13.85 |
| Book Value/Share | $29.94 | – |
| Revenue/Share | $25.96 | $90.46 |
| FCF/Share | $4.24 | $20.96 |
Profitability & Margins
| Metric | ABT | AZN |
|---|---|---|
| ROE | 12.1% | 44.5% |
| ROA | 5.7% | 19.0% |
| ROIC | 8.4% | 36.0% |
| Gross Margin | 56.3% | 81.8% |
| Operating Margin | 17.1% | 21.4% |
| Net Margin | 13.9% | 15.4% |
| EBT Margin | 18.0% | 19.0% |
| Tax Rate | 22.9% | 18.7% |
Financial Health
| Metric | ABT | AZN |
|---|---|---|
| Current Ratio | 1.39x | 0.94x |
| Quick Ratio | 1.01x | 0.72x |
| D/E Ratio | 1.11x | 1.34x |
| Financial Leverage | 2.12x | 2.34x |
| Interest Coverage | 4.1x | – |
| Working Capital | $7.13B | -$1.89B |
Cash Flow
| Metric | ABT | AZN |
|---|---|---|
| Operating Cash Flow | $9.46B | $39.11B |
| Free Cash Flow | $7.38B | $32.48B |
| Capital Spending | -$2.09B | -$6.62B |
| OCF Growth YoY | 5.7% | 32.6% |
| FCF Growth YoY | 10.8% | 0.0% |
| FCF/Sales | 16.4% | 23.2% |
| CapEx/Sales | 4.6% | 4.7% |
Operational Efficiency
| Metric | ABT | AZN |
|---|---|---|
| Asset Turnover | 0.41x | 1.23x |
| Receivables Turnover | 5.5x | 9.2x |
| Inventory Turnover | 2.8x | 3.9x |
| Fixed Assets Turnover | 3.6x | 10.8x |
| Days Sales Outstanding | 66 days | 40 days |
| Days Inventory | 129 days | 94 days |
| Payables Period | – | 362 days |
| Cash Conversion Cycle | – | -229 days |
Income Statement
| Metric | ABT | AZN |
|---|---|---|
| Total Revenue | $45.13B | $140.21B |
| Operating Income | $7.71B | $30.00B |
| Net Income | $6.28B | $21.64B |
| R&D Expense | $2.99B | $34.37B |
| SG&A Expense | $13.01B | $49.70B |
| Cost of Goods Sold | $19.74B | $25.50B |
Dividend & Shareholder Information
| Metric | ABT | AZN |
|---|---|---|
| Dividends Per Share | $2.41 | – |
| Payout Ratio | 67.5% | – |
| Shares Outstanding | 1739M | 1550M |
| Net Income Growth | -53.5% | 89.5% |
| EPS Growth | -53.6% | 89.2% |
ABT vs AZN: stock comparison and AI forecast
Which is bigger, ABT or AZN?
AZN is 1.5 times larger than ABT by market capitalization ($285.01B against $190.23B).
Which is cheaper on earnings, ABT or AZN?
AZN trades at 13.3 times trailing earnings, ABT at 30.6 times.
Which one does Intratio's AI model rank higher, ABT or AZN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.